The biological role and timing of IGFBP3 methylation in CRC is poorly understood; however, recent in vitro studies have reported that methylation-induced silencing of IGFBP3 may lead to significant resistance to cisplatin treatment in lung cancer [42], [43]. This evidence concerns the gene IGFBP3 and lung carcinoma.